To circumvent and overcome the limitations of monoclonal antibody therapy targeting EGFR alone in patients with GBM, we designed this phase I study based on our preclinical data that showed that the arming of ATC with EGFR BiAb exerts potent in vitro anti-tumor activity [11]. Here, EGFR is linked to neoplasm.